On January 2, 2025, Innovent licensed its DLL3-ADC IBI3009 to Roche for $80 million upfront, milestones up to $1 billion, and royalties. ACROBiosystems supports DLL3-targeted therapies, offering DLL3 proteins and stable cell lines to advance ADCs, T-cell engagers, and CAR therapies for SCLC and related diseases.

IBD is a chronic autoimmune digestive disease, including Ulcerative Colitis and Crohn's Disease. Unlock TL1A potential in IBD treatment with ACROBiosystems advanced TL1A Proteins, Stable Cells, Inhibitor Screening Kit. Designed for precise modulation and in-depth analysis, these tools empower researchers to explore TL1A-targeted therapies, paving the way for effective IBD solutions.